Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
ZORPRIN |
| Manufacturer |
|
Par Pharmaceutical, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Salicylate. |
| Generic Name |
|
Aspirin 800mg; pH-dependent release tabs. |
| Indications |
|
Rheumatoid arthritis (RA). Juvenile rheumatoid arthritis (JRA). Spondyloarthropathies. Osteoarthritis (OA). Arthritis and pleurisy of systemic lupus erythematosus (SLE). |
| Children |
|
<25kg: not recommended. ≥25kg: JRA: initially 90–130mg/kg per day in divided doses; target plasma salicylate level 150–300micrograms/mL. |
| Adults |
|
Swallow whole with ≥8oz of fluids. RA, SLE: initially 3g daily in divided doses; target plasma salicylate level 150–300micrograms/mL. OA: up to 3g/day in divided doses. Spondyloarthropathies: up to 4g/day in divided doses. |
| Contraindications |
|
NSAID allergy. Asthma, rhinitis or nasal polyps. Viral infection in children and teenagers. Children with fever or weigh <25 kg. |
| Precautions |
|
Not for antipyresis or short-term analgesia. Severe hepatic or renal dysfunction; avoid. Bleeding disorders. History of GI bleed/peptic ulcer. Diabetes. Gout. Labor and delivery; avoid 1 week before and during. Pregnancy (avoid in 3rd trimester), nursing mothers: not recommended. |
| Interactions |
|
Potentiates anticoagulants, oral hypoglycemics, methotrexate, acetazolamide, valproic acid or highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids, gastric acid secretion inhibitors may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics or uricosurics. Increased bleeding risk with anticoagulants, NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. |
| Adverse Reactions |
|
GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism (eg, tinnitus), dysrhythmias, agitation, cerebral or pulmonary edema, dehydration, hyperkalemia, elevated hepatic enzymes, angioedema, hyperpnea, Reye's syndrome, coagulopathy, others. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
